ArticleMedicine2026
High anion gap and albumin-adjusted anion gap are associated with hospital mortality in intensive care unit patients with liver cirrhosis: A retrospective cohort.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Data of patients with liver cirrhosis (LC) were collected from the Medical Information Mart for Intensive Care III database to explore whether anion gap (AG) and albumin-adjusted AG (AA-AG) values were associated with outcomes in patients with LC. We retrospectively analyzed data of adult patients with LC. Based on the AG and AA-AG level, patients were then divided into groups according to third percentile. Lowess smoothing was first applied to visualize the crude relationship between AG or AA-AG and inhospital mortality. Survival curves were generated with the Kaplan-Meier and compared by log-rank test. Multivariable logistic regression was constructed to quantify the independent effect of elevated or AA-AG on hospital mortality after adjustment multiple confounding factors. Model discrimination was assessed with area under the receiver operating characteristic curve (AUC) and 95% confidence intervals (CI). Lowess Smoothing technique showed that AG and AA-AG were associated with hospital mortality for patients with LC. Crude outcomes and Kaplan-Meier survival curve analysis revealed that hospital survival rates of patients with high AG and AA-AG values were significantly lower (P < .001) compared to those with lower values. After adjusting for multiple confounding factors, analysis revealed that elevated AG (>19 mmol/L) was an independent risk factor for increased inhospital mortality in patients with LC (odds ratio: 1.887 [95% CI: 1.208-2.95]; P < .05), and elevated AA-AG (>21.5 mmol/L) was an independent risk factor for increased inhospital mortality in patients with LC (odds ratio: 1.892 [95% CI: 1.229-2.912]; P < .05). Specifically, the AG demonstrated an AUC of 0.6704 (95% CI: 0.63-0.71) in predicting hospital mortality. The Model for End-Stage Liver Disease (MELD), on the other hand, exhibited a higher predictive accuracy with an AUC of 0.7186 (95% CI: 0.68-0.76). When AG and MELD were combined, the predictive performance further improved, yielding an AUC of 0.7302 (95% CI: 0.69-0.77). Similarly, the AA-AG showed an AUC of 0.684 (95% CI: 0.64-0.73) in predicting hospital mortality, and when combined with the MELD, the AUC increased to 0.7376 (95% CI: 0.70-0.78). Elevated serum AG (≥19 mmol/L) and AA-AG (≥21.5 mmol/L) were risk factors for inhospital mortality among critically ill patients with LC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.